Epidarex Capital funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.
Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11 Data show, for the first time, that INDY inhibition attenuates diet-induced NASH and mINDY inhibitors may be a novel ... Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutic...
Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer